Your browser doesn't support javascript.
loading
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial.
Joharatnam-Hogan, Nalinie; Cafferty, Fay; Hubner, Richard; Swinson, Daniel; Sothi, Sharmila; Gupta, Kamalnayan; Falk, Stephen; Patel, Kinnari; Warner, Nicola; Kunene, Victoria; Rowley, Sam; Khabra, Komel; Underwood, Tim; Jankowski, Janusz; Bridgewater, John; Crossley, Anne; Henson, Verity; Berkman, Lindy; Gilbert, Duncan; Kynaston, Howard; Ring, Alistair; Cameron, David; Din, Farhat; Graham, Janet; Iveson, Timothy; Adams, Richard; Thomas, Anne; Wilson, Richard; Pramesh, C S; Langley, Ruth.
Afiliación
  • Joharatnam-Hogan N; MRC Clinical Trials Unit, University College London, UK.
  • Cafferty F; MRC Clinical Trials Unit, University College London, UK.
  • Hubner R; The Christie Hospital, Manchester, UK.
  • Swinson D; St James University Hospital, Leeds, UK.
  • Sothi S; University Hospital Coventry and Warwickshire, UK.
  • Gupta K; Worcestershire Royal Hospital, Worcester, UK.
  • Falk S; Bristol Haematology & Oncology Centre, Bristol, UK.
  • Patel K; Churchill Hospital, Oxford, UK.
  • Warner N; Stoke Mandeville Hospital, Aylesbury, UK.
  • Kunene V; Manor Hospital, Walsall, UK.
  • Rowley S; MRC Clinical Trials Unit, University College London, UK.
  • Khabra K; MRC Clinical Trials Unit, University College London, UK.
  • Underwood T; University of Southampton, Southampton, UK.
  • Jankowski J; Gastroenterology Unit, Morecambe Bay University Hospitals NHS Trust, UK; National Institute for Health and Care Excellence, London, UK.
  • Bridgewater J; University College Hospital London, UK.
  • Crossley A; St James University Hospital, Leeds, UK.
  • Henson V; Bristol Haematology & Oncology Centre, Bristol, UK.
  • Berkman L; NCRI Consumer Liaison Group, London, UK.
  • Gilbert D; MRC Clinical Trials Unit, University College London, UK.
  • Kynaston H; Cardiff University, Cardiff, UK.
  • Ring A; Royal Marsden Hospital, London, UK.
  • Cameron D; Cancer Research UK Edinburgh Centre, MRC Institute of Genetics & Molecular Medicine, Western General Hospital, Edinburgh, UK.
  • Din F; Cancer Research UK Edinburgh Centre, MRC Institute of Genetics & Molecular Medicine, Western General Hospital, Edinburgh, UK.
  • Graham J; Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Iveson T; Southampton General Hospital, UK.
  • Adams R; Velindre Cancer Centre, Cardiff, UK.
  • Thomas A; Leicester Royal Infirmary, Leicester, UK.
  • Wilson R; University of Glasgow, Glasgow, UK.
  • Pramesh CS; Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India.
  • Langley R; MRC Clinical Trials Unit, University College London, UK. Electronic address: ruth.langley@ucl.ac.uk.
Lancet Gastroenterol Hepatol ; 4(11): 854-862, 2019 11.
Article en En | MEDLINE | ID: mdl-31477558
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Aspirina / Fibrinolíticos / Neoplasias / Antineoplásicos Tipo de estudio: Clinical_trials / Guideline / Health_technology_assessment Límite: Aged / Female / Humans / Male Idioma: En Revista: Lancet Gastroenterol Hepatol Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Aspirina / Fibrinolíticos / Neoplasias / Antineoplásicos Tipo de estudio: Clinical_trials / Guideline / Health_technology_assessment Límite: Aged / Female / Humans / Male Idioma: En Revista: Lancet Gastroenterol Hepatol Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido